

Amendments to the Claims:

This listing of claims will replace all prior version and listings of claims in the application.

Listing of Claims:

1. (Previously presented) A method of ameliorating symptoms associated with the growth of bone metastasized cancer or bone-originated cancer, comprising administering to an individual in need thereof a medicament comprising an amount of a parathyroid hormone receptor agonist effective to reduce pain;

wherein said agonist comprises at least 25 amino acids and comprises at least 29% identity with SEQ ID NO: 1;

wherein said agonist comprises an activation domain comprising amino acid sequence X1-V-S-E-X2-Q-X3, wherein X1 is selected from S or A, X2 is selected from I or H, and wherein X3 is selected from L or F; and

wherein said agonist comprises an receptor binding domain comprising amino acid sequence L-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13, wherein X4 is selected from R, H, or E, wherein X5 is selected from K, H, or Aib, wherein X6 is selected from K or L, wherein X7 is selected from I or L, wherein X8 is selected from A, Q, or E, wherein X9 is selected from D, E, K, or L, wherein X10 is selected from V, I, or L, wherein X11 is selected from H or Thi, wherein X12 is selected from N or T, wherein X13 is selected from F, A, or Y.

2. (Canceled)

3. (Previously presented) The method according to claim 1, wherein said parathyroid hormone receptor agonist is PTH or an analogue thereof.

4. (Previously presented) The method according to claim 3, wherein said parathyroid hormone or an analogue thereof is parathyroid hormone (1-34).

5. (Previously presented) The method according to claim 1, wherein said parathyroid hormone receptor agonist is parathyroid hormone-related protein or an analogue thereof.

6. (Previously presented) The method according to claim 1, wherein said individual has bone metastasized cancer.

7. (Previously presented) The method according to claim 6, wherein said bone metastasized cancer is breast cancer, prostate cancer, lung cancer, kidney cancer, thyroid cancer or myeloma.

8. (Previously presented) The method according to claim 1, wherein said individual has bone-originated cancer.

9. (Previously presented) The method according to claim 1, wherein said bone originated cancer is sarcoma.

10. (Previously presented) The method according to claim 1, wherein the amount of the parathyroid hormone receptor agonist is from 0.1 to 1000 micrograms.

11. (Previously presented) The method according to claim 10, wherein the amount of the parathyroid hormone receptor agonist is from 20 to 200 micrograms.

12. (Previously presented) The method according to claim 3, wherein said parathyroid hormone or an analogue thereof is teriparatide acetate.

13. (Withdrawn) A medicament for ameliorating symptoms associated with the growth of bone metastasized cancer or bone-originated cancer, comprising an amount of a PTH receptor agonist effective to reduce bone loss, reduce bone fracturing, and/or reduce pain in an individual in need thereof.

14. (Withdrawn) The medicament according to claim 13, wherein said amount is effective to reduce pain.

15. (Withdrawn) The medicament according to claim 13, wherein said PTH receptor agonist is PTH or an analogue thereof.

16. (Withdrawn) The medicament according to claim 15, wherein said PTH or an analogue thereof is PTH(1-34).

17. (Withdrawn) The medicament according to claim 15, wherein said PTH or an analogue thereof is teriparatide acetate.

18. (Withdrawn) The medicament according to claim 13, wherein said PTH receptor agonist is parathyroid hormone-related protein or an analogue thereof.

19. (Withdrawn) The medicament according to claim 13, comprising from 0.1 to 1000 micrograms of the PTH receptor agonist.

20. (Withdrawn) The medicament according to claim 13, comprising from 20 to 200 micrograms of the PTH receptor agonist.

21. (Currently amended) The method of claim 1, wherein the activation domain is selected from the group consisting of amino acids SVSEIQ (aa 1-5 of SEQIDNO:1), AVSEIQ (aa 1-5 of SEQIDNO:2), or AVSEHQ (aa 1-5 of SEQIDNO:3).

22. (Currently amended) The method of claim 1, wherein the receptor binding domain comprises the amino acids selected from the group consisting of:

LRKKLQDVHNF (aa 24-34 of SEQIDNO:1),

LRKKLQDVHNY (aa 24-34 of SEQIDNO:4),

LHHLIAEIHTA (aa 24-34 of SEQIDNO:3),

LEKLLLEKLHNF (aa 24-34 of SEQIDNO:5),

LRKLLQDLHNF (aa 24-34 of SEQIDNO:7),

LHAibLIAEIHTA (aa 24-34 of SEQIDNO:8),

LEKLLLEKLThiTA (aa 24-34 of SEQIDNO:9),

LEKLLLELLHTA (aa 24-34 of SEQIDNO:10),

Reply to Office Action of 04/27/2009

LHLLLAELHTA (aa 24-34 of SEQIDNO:11),

LEKLEIKHTA (aa 24-34 of SEQIDNO:12), or

LHLLIAEHTA (aa 24-34 of SEQIDNO:43).

23. (Currently amended) The method of claim 1, wherein the parathyroid hormone receptor agonist is selected from the group consisting of:

SEQIDNO_1 — SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF (SEQIDNO:1),
 SEQIDNO_2 — AVSEIQFMHNLGKHLSSMERVEWLRKKLQDVHNF (SEQIDNO:2),
 SEQIDNO_3 — AVSEHQLLHDKGKSIQDLRRRFFLHLLIAEHTA (SEQIDNO:3),
 SEQIDNO_4 — AVSEIQFXHNLGKHLSSXERVEXLRKKLQDVHNY (SEQIDNO:4),
 SEQIDNO_5 — SVSEIQLMHNLGKHLNSMERVELLEKLEKLNHF (SEQIDNO:5),
 SEQIDNO_6 — SVSEIQLMHNLGKHLNSMERVEWLEKLEKLVHNF (SEQIDNO:6),
 SEQIDNO_7 — SVSEIQLMHNLGKHLNSMERVELLRKKLQDLHNF (SEQIDNO:7),
 SEQIDNO_8 — AVSEHQLLHDKGKSIQDLRRRFFLHLLIAEHTA (SEQIDNO:8),
 SEQIDNO_9 — AVSEHQLLHDKGKSIQDLRRRELLEKLEKLTXTA (SEQIDNO:9),
 SEQIDNO_10 — AVSEHQLLHDKGKSIQDLRRRELLEKLELLHTA (SEQIDNO:10),
 SEQIDNO_11 — AVSEHQLLHDKGKSIQDLRRRFFLHLLIAELHTA (SEQIDNO:11),
 SEQIDNO_12 — AVSEHQLLHDKGKSIQDLRRREFLEKLEIKHTA (SEQIDNO:12),
 SEQIDNO_13 — AVSEIQFXHNLGKHLSSXERVEXLRKKLQDVHNY (SEQIDNO:13),
 SEQIDNO_14 — AVSEIQFXHNLGKHLSSXXRVEXLRKKLQDVHNY (SEQIDNO:14),
 SEQIDNO_15 — AVSEIQFXHNLGKHLSSXXRVEXLRKKLQDVHNY (SEQIDNO:15),
 SEQIDNO_16 — AVSEIQFXHNLGKHLSSXXRVEXLRKKLQDVHNY (SEQIDNO:16),
 SEQIDNO_17 — AVSEIQFXHNLGKHLSSXXRVEXLRKKLQDVHNY (SEQIDNO:17),
 SEQIDNO_18 — AVSEIQFMHNLGKHLSSXERVEWLRKKLQDVHNF (SEQIDNO:18),
 SEQIDNO_19 — AVSEIQFMHNLGKHLSSXEXVEWLRKKLQDVHNF (SEQIDNO:19),
 SEQIDNO_20 — AVSEIQFMHNLGKHLSSXERVEWLRKKLQDVHNF (SEQIDNO:20),
 SEQIDNO_21 — AVSEIQFMHNLGKHLSSXERVEWLRKKLQDVHNF (SEQIDNO:21),
 SEQIDNO_22 — AVSEIQFMHNLGKHLSSXXRVWLRKKLQDVHNF (SEQIDNO:22),
 SEQIDNO_23 — AVSEIQFMHNLGKHLSSXERVEWLRKKLQDVHNF (SEQIDNO:23),
 SEQIDNO_24 — AVSEIQFMHNLGKHLSSXERVEWLRKKLQDVHNF (SEQIDNO:24),
 SEQIDNO_25 — AVSEIQFMHNLGKHLSSXXRVWLRKKLQDVHNF (SEQIDNO:25),
 SEQIDNO_26 — AVSEIQFMHNLGKHLSSXERVEWLRKKLQDVHNF (SEQIDNO:26),
 SEQIDNO_27 — AVSEIQFMHNLGKHLSSXXRVWLRKKLQDVHNF (SEQIDNO:27),
 SEQIDNO_28 — AVSEIQFMHNLGKHLSSXXRVWLRKKLQDVHNF (SEQIDNO:28),
 SEQIDNO_29 — AVSEIQFMHNLGKHLSSXERVEWLRKKLQDVHNF (SEQIDNO:29),
 SEQIDNO_30 — AVSEIQFMHNLGKHLSSXXRVWLRKKLQDVHNF (SEQIDNO:30),
 SEQIDNO_31 — AVSEIQFMHNLGKHLSSXXRVWLRKKLQDVHNF (SEQIDNO:31),
 SEQIDNO_32 — AVSEIQFMHNLGKHLSSXXRVWLRKKLQDVHNF (SEQIDNO:32),
 SEQIDNO_33 — AVSEIQFMHNLGKHLSSXXRVWLRKKLQDVHNF (SEQIDNO:33),
 SEQIDNO_34 — AVSEIQFMHNLGKHLSSXXRVWLRKKLQDVHNF (SEQIDNO:34),

Reply to Office Action of 04/27/2009

SEQIDNO_35———AVSEIQFMHNLGKHLXXXXRVEWLRRKKLQDVHNF (SEQIDNO:35),
SEQIDNO_36———AVSEIQFMHNLGKHLXXXXRVEWLRRKKLQDVHNF (SEQIDNO:36),
SEQIDNO_37———AVSEIQFMHNLGKHLXXXXRVEWLRRKKLQDVHNF (SEQIDNO:37),
SEQIDNO_38———AVSEIQFMHNLGKHLXXXRVEWLRRKKLQDVHNF (SEQIDNO:38),
SEQIDNO_39———AVSEIQFMHNLGKHLSSXXRVEWLRRKKLQDVHNF (SEQIDNO:39),
SEQIDNO_40———AVSEIQFMHNLGKHLXXXXRVEWLRRKKLQDVHNF (SEQIDNO:40),
SEQIDNO_41———AVSEIQFMHNLGKHLXXXXRVEWLRRKKLQDVHNF (SEQIDNO:41),
SEQIDNO_42———SVSEIQLXHNLXKHLNSXERVEXLRKKLQDVHNY (SEQIDNO:42),
or
SEQIDNO_43———AVSEHQLLHDKXKSIQDLRRRFFLHHLIAEIHTA (SEQIDNO:43).